Compare NMFC & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMFC | VIR |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.8M | 1.0B |
| IPO Year | N/A | 2019 |
| Metric | NMFC | VIR |
|---|---|---|
| Price | $8.16 | $9.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $10.00 | ★ $29.13 |
| AVG Volume (30 Days) | 1.3M | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 15.80% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $68,556,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $131.58 |
| P/E Ratio | $12.51 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.91 | $4.16 |
| 52 Week High | $11.98 | $9.84 |
| Indicator | NMFC | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 76.06 |
| Support Level | $7.91 | $4.54 |
| Resistance Level | $8.68 | N/A |
| Average True Range (ATR) | 0.25 | 0.50 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 33.77 | 98.46 |
New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.